In conclusion, our study suggests that the CCL5/CCR5/CYP1A1 pathway is activated during combination therapy to mediate metabolic reprogramming of liver cancer cells to resist lenvatinib (Figure 8). This evidence concerns the gene CYP1A1 and liver cancer.